文献速递淋巴瘤造血干细胞移植与细胞治疗

帕博利珠单抗治疗CD19 CAR-T后复发或难治的B细胞淋巴瘤

Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
PubMed 文献 · Blood · 2022-01-01

这项研究纳入12例CD19 CAR-T治疗后难治(n=9)或复发(n=3)的B细胞淋巴瘤患者,给予帕博利珠单抗200 mg静脉注射每3周一次。帕博利珠单抗耐受良好,最佳总缓解率为25%(3/12,1例完全缓解,2例部分缓解),33%(4/12)患者获得临床获益。免疫分析显示缓解者CAR-T细胞活化与增殖增加、耗竭减少。

要点

  • CD19 CAR-T后难治或复发的B细胞淋巴瘤患者中,帕博利珠单抗最佳总缓解率为25%。
  • 帕博利珠单抗耐受良好,仅3例(25%)出现≥3级中性粒细胞减少。
  • 临床获益者CAR-T细胞比例和CAR19转基因水平升高,T细胞耗竭减少。

核心结论

  • CD19 CAR-T治疗后使用帕博利珠单抗阻断PD1看来是安全的,并可能使部分难治或复发的B细胞淋巴瘤患者获得临床缓解。

研究设计与样本

  • 研究治疗了12例CD19 CAR-T(4-1BB共刺激)治疗后难治(n=9)或复发(n=3)的B细胞淋巴瘤患者。
  • 帕博利珠单抗剂量为200 mg静脉注射,每3周一次。
  • CAR-T输注至首次帕博利珠单抗的中位时间为3.3个月(范围0.4-42.8个月)。
  • 试验注册号为NCT02650999。

主要发现

  • 帕博利珠单抗耐受良好,唯一与帕博利珠单抗相关的≥3级不良事件为中性粒细胞减少(n=3;25%)。
  • 帕博利珠单抗后最佳总缓解率为25%(3/12;1例完全缓解,2例部分缓解)。
  • 1例(8%)患者疾病稳定,因此4/12(33%)患者获得临床获益。
  • 临床获益的4例患者中,经CyTOF检测CAR-T细胞百分比升高;其中3/4患者同时经定量PCR检测CAR19转基因水平升高。
  • CyTOF深度免疫分析显示临床缓解者CAR-T细胞活化和增殖增加、T细胞耗竭减少。

临床怎么用

  • 对于CD19 CAR-T治疗后难治或复发的B细胞淋巴瘤患者,可考虑帕博利珠单抗治疗,但需注意其缓解率有限。
  • 治疗期间应监测中性粒细胞减少等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed chimeric antigen receptor-modified (CAR T) T cells achieve durable remissions in about 30% to 40% of relapsed/refractory large B-cell lymphomas. T-cell exhaustion and/or an immunosuppressive tumor microenvironment may contribute to CAR T-cell failure. Pembrolizumab, an anti-PD1 immune checkpoint inhibitor, may reverse T-cell exhaustion after CAR T-cell therapy. We treated 12 patients with B-cell lymphomas who were either refractory to (n = 9) or relapsed after (n = 3) CD19-directed CAR T-cell (4-1BB-costimulated) therapy with pembrolizumab 200 mg IV every 3 weeks. Median time from CAR T-cell infusion to first pembrolizumab dose was 3.3 months (range, 0.4-42.8 months). Pembrolizumab was well tolerated, and the only grade ≥3 adverse events related to pembrolizumab were neutropenia (n = 3; 25%). Best overall response rate after pembrolizumab was 25% (3 of 12 patients; 1 complete response; 2 partial responses). One (8%) patient had stable disease; thus, 4 of 12 (33%) patients had clinical benefit. After pembrolizumab, 4 patients with clinical benefit had an increase in percentage of CAR T cells by mass cytometry by time of flight (CyTOF); 3 of 4 of these patients also had increases in CAR19 transgene levels by quantitative polymerase chain reaction. Deep immune profiling using CyTOF revealed increased CAR T-cell activation and proliferation and less T-cell exhaustion in clinical responders. Together, PD1 blockade with pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in some patients with B-cell lymphomas refractory to or relapsed after CAR T-cell therapy. This trial was registered at www.clinicaltrials.gove as #NCT02650999.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chong EA, Alanio C, Svoboda J, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022. PMID: 34496014. doi:10.1182/blood.2021012634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。